Skip to main content
Jeffrey Neul, MD, Child Neurology, Nashville, TN, Vanderbilt University Medical Center

JeffreyLorenzNeulMDPh.D.

Child Neurology Nashville, TN

Director, Vanderbilt Kennedy Center

Dr. Neul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Neul's full profile

Already have an account?

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineResidency, Child Neurology, 2000 - 2005
  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Child Neurology, 2001 - 2004
  • Baylor College of Medicine
    Baylor College of MedicineInternship, Transitional Year, 2000 - 2001
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2006 - 2025
  • TN State Medical License
    TN State Medical License 2018 - 2025
  • CA State Medical License
    CA State Medical License 2014 - 2022
  • American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology

Awards, Honors, & Recognition

  • Circle of Angels award for dedication to research on Rett syndrome International Rett Syndrome Foundation, 2011
  • Philip R. Dodge Young Investigator Award Child Neurology Society, 2009

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • First Treatment Approved for Rare Genetic Neurologic Disorder
    First Treatment Approved for Rare Genetic Neurologic DisorderMarch 13th, 2023
  • Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (Trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
    Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (Trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderMarch 11th, 2023
  • Trofinetide Shows Promise in Rett Syndrome
    Trofinetide Shows Promise in Rett SyndromeApril 6th, 2022
  • Join now to see all

Grant Support

  • Rett Syndrome, MECP2 Duplications, and Rett-related Disorders Natural HistoryEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2014–Present
  • Baylor Intellectual and Developmental Disabilities Research CentersEEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2014–Present
  • Identification of Genetic Modifiers in Rett Syndrome.Rett Syndrome Research Trust2013–Present
  • NNZ-2566 in Adult Rett SyndromeNeuren Pharmaceuticals2012–Present
  • A randomized, double-blind placebo controlled trial of NNZ-2566 (IGF-1{1-3}, glycyl-L-2-methylprolyl-L-glutamine acid) with open label extension in adults with Rett syndromeInternational Rett Syndrome Foundation2012–Present
  • Nonsense suppression as a therapeutic approach to Rett syndromeInternational Rett Syndrome Foundation2012–Present
  • Creation of a DNA repository for Rett syndromeInternational Rett Syndrome Foundation2012–2014
  • Characterization Of Autonomic Dysfunction In Rett Syndrome And Other MECP2 DisordEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2012
  • Analysis Of The Dopamine System In Rett SyndromeNational Institute Of Neurological Disorders And Stroke2005–2009

Professional Memberships

Hospital Affiliations

Industry Relationships

  • Consultant, TakedaAdvise on design of clinical trials in neurodevelopmental disorders